EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Jianpi Jiedu Xiaozheng Fang Regulates Hepatocellular Carcinoma Proliferation and Metastasis Based on Network Pharmacology

Bin Li iD, Han-Qian Shi, Rui Luo iD, Zi-Qi Zhang, Xiao-Chen Dong, Xiao-Hua Li, Shi-Qin Ye, Chong Zhong

Journal of Cellular and Molecular Medicine · 2026-03 · 30 (5)

DOI: 10.1111/jcmm.71040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 07.03.2026. Verfasst von Bin Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou University of Chinese Medicine, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Network Pharmacology, Drugs, Chinese Herbal. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 'Yulong Talent' Cultivation Program of Beijing University of Chinese Medicine Shenzhen Hospital (Longgang).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma ( HCC ) is a primary malignant tumour that impacts patients' quality of life. Currently, clinical experience from The First Affiliated Hospital of Guangzhou University of Chinese Medicine suggests that Jianpi Jiedu Xiaozheng Fang ( JPJDXZF ) demonstrates promising efficacy in the treatment of HCC . We aimed to explore the mechanisms of JPJDXZF in HCC based on network pharmacology. The components and their relevant targets of JPJDXZF were identified using databases such as SymMap , TCMID , TCMSP , and TCM ‐ ID . Following ADME screening, 1443 active components of JPJDXZF were identified, and 435 corresponding drug targets were predicted using the SwissTargetPrediction database. Subsequently, prognosis‐related differentially expressed genes ( DEGs ) associated with HCC were analyzed using TCGA and GTEx datasets, and a gene expression matrix was derived. Key genes involved in HCC regulation were identified, and functional analyses were performed. Furthermore, we explored the regulatory effects of JPJDXZF at the cellular, organoid, and animal levels. We identified 18 intersecting genes between HCC prognosis‐related genes and JPJDXZF ‐target genes. Venn diagram analysis successfully identified BIRC5 and CYP2E1 as two potential targets for JPJDXZF in treating HCC . Pathway enrichment analysis indicated that the core targets of JPJDXZF were enriched in multiple signalling pathways, including the Hippo pathway, in which BIRC5 is involved as a downstream regulatory gene. In in vitro experiments, JPJDXZF ‐containing serum significantly reduced the viability and migration of HepG2 and MHCC97 ‐H cells, leading to a decrease in organoid diameter and ATP activity in HCC organoids. In in vivo experiments, tumours in nude mice treated with JPJDXZF exhibited reduced volume and weight, along with decreased expression of BIRC5 and Hippo pathway effectors YAP and TAZ . At the mechanistic level, JPJDXZF treatment was associated with altered Hippo pathway–related signalling, accompanied by reduced YAP / TAZ activity and changes in BIRC5 expression, together with effects on HCC cell proliferation and apoptosis. In addition, siMST1 /2 interference and EMT inhibitor‐1 treatment partially attenuated the effects of JPJDXZF on cell viability, migration, and apoptosis. J PJDXZF regulates BIRC5 expression in association with Hippo pathway activity in HCC . In vitro, in vivo, and molecular mechanism analyses support JPJDXZF as a potential therapeutic strategy for HCC by modulating key proteins in the Hippo pathway, thus affecting HCC cell proliferation, apoptosis, and migration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsNetwork PharmacologyDrugs, Chinese HerbalHumansCell ProliferationGene Expression Regulation, NeoplasticAnimalsCell MovementMiceNeoplasm MetastasisSignal TransductionCell Line, TumorPrognosisXenograft Model Antitumor AssaysMice, NudeApoptosis

Stichwörter der Autor:innen

BIRC5JPJDXZFhepatocellular carcinomahippo pathwayorganoid

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Guangzhou University of Chinese Medicine, Guangzhou, China.
  • First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Beijing University of Chinese Medicine Shenzhen Hospital (Longgang), Shenzhen, China.
  • Department of Biliary-Pancreatic Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.

ORCID-Profile: Bin Li, Rui Luo

Förderung

  • 'Yulong Talent' Cultivation Program of Beijing University of Chinese Medicine Shenzhen Hospital (Longgang)

Zitieren

APA

Li, B., Shi, H. Q., Luo, R., Zhang, Z. Q., Dong, X. C., Li, X. H., Ye, S. Q., & Zhong, C. (2026). Jianpi Jiedu Xiaozheng Fang Regulates Hepatocellular Carcinoma Proliferation and Metastasis Based on Network Pharmacology. Journal of Cellular and Molecular Medicine, 30(5). https://doi.org/10.1111/jcmm.71040

Vancouver

Li B, Shi HQ, Luo R, Zhang ZQ, Dong XC, Li XH, et al. Jianpi Jiedu Xiaozheng Fang Regulates Hepatocellular Carcinoma Proliferation and Metastasis Based on Network Pharmacology. Journal of Cellular and Molecular Medicine. 2026;30(5). doi:10.1111/jcmm.71040

BibTeX
@article{Li2026,
  author = {Li, Bin and Shi, Han-Qian and Luo, Rui and Zhang, Zi-Qi and Dong, Xiao-Chen and Li, Xiao-Hua and Ye, Shi-Qin and Zhong, Chong},
  title = {Jianpi Jiedu Xiaozheng Fang Regulates Hepatocellular Carcinoma Proliferation and Metastasis Based on Network Pharmacology},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {5},
  doi = {10.1111/jcmm.71040}
}
Kostenlos starten →